TY - JOUR
T1 - Durability of antidepressant response to repetitive transcranial magnetic stimulation
T2 - Systematic review and meta-analysis
AU - Senova, Suhan
AU - Cotovio, Gonçalo
AU - Pascual-Leone, Alvaro
AU - Oliveira-Maia, Albino J.
PY - 2019/1
Y1 - 2019/1
N2 - Background: The therapeutic options for treatment-resistant depression (TRD) encompass a range of neuromodulatory techniques, including repetitive transcranial magnetic stimulation (rTMS). While rTMS is safe and has documented short-term efficacy, durability of antidepressant effects is poorly established. Objective: Assess existing evidence regarding durability of rTMS-induced antidepressant response. Methods: We performed a systematic review of studies reporting antidepressant outcome measures collected three or more months after the end of an induction course of rTMS for depression. Among responders to the induction course, we used a meta-analytic approach to assess response rates at 3 (m3), 6 (m6) or 12 (m12) months after induction, and studied predictors of responder rates using meta-regression. Results: Nineteen studies published between 2002 and 2018 were included. Eighteen were eligible for analysis at m3 (732 patients) and m6 (695 patients) and 9 at m12 (247 patients). Among initial responders, 66.5% sustained response at m3 (95% CI = 57.1–74.8%, I2 = 27.6%), 52.9% at m6 (95% CI = 40.3–65%, I2 = 0%), and 46.3% at m12 (95% CI = 32.6–60.7%, I2 = 0%), in the absence of any major bias. Random-effects meta-regressions further demonstrated that a higher proportion of women, as well as receipt of maintenance treatment, predicted higher responder rates at specific time-points. Conclusions: rTMS is a durable treatment for depression, with sustained responder rates of 50% up to 1 year after a successful induction course of treatment. Maintenance treatment may enhance the durability of the antidepressant effects of rTMS, and should be considered in clinical practice, as well as systematically explored in future clinical trials.
AB - Background: The therapeutic options for treatment-resistant depression (TRD) encompass a range of neuromodulatory techniques, including repetitive transcranial magnetic stimulation (rTMS). While rTMS is safe and has documented short-term efficacy, durability of antidepressant effects is poorly established. Objective: Assess existing evidence regarding durability of rTMS-induced antidepressant response. Methods: We performed a systematic review of studies reporting antidepressant outcome measures collected three or more months after the end of an induction course of rTMS for depression. Among responders to the induction course, we used a meta-analytic approach to assess response rates at 3 (m3), 6 (m6) or 12 (m12) months after induction, and studied predictors of responder rates using meta-regression. Results: Nineteen studies published between 2002 and 2018 were included. Eighteen were eligible for analysis at m3 (732 patients) and m6 (695 patients) and 9 at m12 (247 patients). Among initial responders, 66.5% sustained response at m3 (95% CI = 57.1–74.8%, I2 = 27.6%), 52.9% at m6 (95% CI = 40.3–65%, I2 = 0%), and 46.3% at m12 (95% CI = 32.6–60.7%, I2 = 0%), in the absence of any major bias. Random-effects meta-regressions further demonstrated that a higher proportion of women, as well as receipt of maintenance treatment, predicted higher responder rates at specific time-points. Conclusions: rTMS is a durable treatment for depression, with sustained responder rates of 50% up to 1 year after a successful induction course of treatment. Maintenance treatment may enhance the durability of the antidepressant effects of rTMS, and should be considered in clinical practice, as well as systematically explored in future clinical trials.
KW - Depression
KW - Durability
KW - Meta-analysis
KW - Relapse
KW - Repetitive transcranial magnetic stimulation
UR - http://www.scopus.com/inward/record.url?scp=85055033465&partnerID=8YFLogxK
U2 - 10.1016/j.brs.2018.10.001
DO - 10.1016/j.brs.2018.10.001
M3 - Article
C2 - 30344109
AN - SCOPUS:85055033465
SN - 1935-861X
VL - 12
SP - 119
EP - 128
JO - Brain Stimulation
JF - Brain Stimulation
IS - 1
ER -